8MW2311

8MW2311 · Mabwell (Shanghai) Bioscience Co., Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 8MW2311, covering 2024-11-20 to 2024-11-20. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]